Statement of Principles concerning malignant neoplasm of the testis and paratesticular tissues No. 3 of 2015

Administered by Department of Veterans' Affairs

Legislation au F2014L01813 Not in force Legislative Instrument

Legislation content

REPATRIATION MEDICAL AUTHORITY

 

INSTRUMENT NO. 3 of 2015

 

VETERANS’ ENTITLEMENTS ACT 1986

MILITARY REHABILITATION AND COMPENSATION ACT 2004

 

EXPLANATORY NOTES FOR TABLING

 

 

  1. The Repatriation Medical Authority (the Authority), under subsection 196B(8) of the Veterans' Entitlements Act 1986 (the VEA), revokes Instrument No. 15 of 2004, determined under subsection 196B(2) of the VEA concerning malignant neoplasm of the testis and paratesticular tissues.
  2. The Authority is of the view that there is sound medical-scientific evidence that indicates that malignant neoplasm of the testis and paratesticular tissues and death from malignant neoplasm of the testis and paratesticular tissues can be related to particular kinds of service.  The Authority has therefore determined pursuant to subsection 196B(2) of the VEA a Statement of Principles, Instrument No. 3 of 2015 concerning malignant neoplasm of the testis and paratesticular tissues.  This Instrument will in effect replace the revoked Statement of Principles.
  3. The provisions of the Military Rehabilitation and Compensation Act 2004 (the MRCA) relating to claims for compensation commenced on 1 July 2004.  Claims under section 319 of the MRCA for acceptance of liability for a service injury sustained, a service disease contracted or service death on or after 1 July 2004 are determined by the Military Rehabilitation and Compensation Commission by reference to Statements of Principles issued by the Authority pursuant to the VEA.
  4. The Statement of Principles sets out the factors that must as a minimum exist, and which of those factors must be related to the following kinds of service rendered by a person:

 operational service under the VEA;

 peacekeeping service under the VEA;

 hazardous service under the VEA;

 British nuclear test defence service under the VEA;

 warlike service under the MRCA;

 non-warlike service under the MRCA,

before it can be said that a reasonable hypothesis has been raised connecting malignant neoplasm of the testis and paratesticular tissues or death from malignant neoplasm of the testis and paratesticular tissues, with the circumstances of that service.

5.             This Instrument results from an investigation notified by the Authority in the Government Notices Gazette of 18 May 2011 concerning malignant neoplasm of the testis and paratesticular tissues in accordance with section 196G of the VEA.  The investigation involved an examination of the sound medical-scientific evidence now available to the Authority, including the sound medical-scientific evidence it has previously considered.

6.             The contents of this Instrument are in similar terms as the revoked Instrument.  Comparing this Instrument and the revoked Instrument, the differences include:

  • adopting the latest revised Instrument format, which commenced in 2005;
  • deleting the ICD code from the Instrument header;
  • new factor 6(a) concerning 'human immunodeficiency virus';
  • revising the definitions of 'ICD-10-AM code' and 'relevant service' in clause 9; and
  • specifying a date of effect for the Instrument in clause 11.

7.             Further changes to the format of the Instrument reflect the commencement of the MRCA and clarify that pursuant to subsection 196B(3A) of the VEA, the Statement of Principles has been determined for the purposes of both the VEA and the MRCA.

8.             Prior to determining this Instrument, the Authority advertised its intention to undertake an investigation in relation to malignant neoplasm of the testis and paratesticular tissues in the Government Notices Gazette of 18 May 2011, and circulated a copy of the notice of intention to investigate to a wide range of organisations representing veterans, service personnel and their dependants.  The Authority invited submissions from the Repatriation Commission, organisations and persons referred to in section 196E of the VEA, and any person having expertise in the field.  No submissions were received for consideration by the Authority during the investigation.

9.             This instrument is compatible with the Human Rights and Freedoms recognised or declared in the International Instruments listed in Section 3 of the Human Rights (Parliamentary Scrutiny) Act 2011. A Statement of Compatibility with Human Rights follows.

10.         The determining of this Instrument finalises the investigation in relation to malignant neoplasm of the testis and paratesticular tissues as advertised in the Government Notices Gazette of 18 May 2011.

11.         A list of references relating to the above condition is available to any person or organisation referred to in subsection 196E(1)(a) to (c) of the VEA.  Any such request must be made in writing to the Repatriation Medical Authority at the following address:

The Registrar

Repatriation Medical Authority

GPO Box 1014

BRISBANE    QLD    4001

Statement of Compatibility with Human Rights

(Prepared in accordance with Part 3 of the Human Rights (Parliamentary Scrutiny) Act 2011)

 

Instrument No.:   Statement of Principles No. 3 of 2015

Kind of Injury, Disease or Death: Malignant neoplasm of the testis and paratesticular tissues

 

This Legislative Instrument is compatible with the human rights and freedoms recognised or declared in the international instruments listed in section 3 of the Human Rights (Parliamentary Scrutiny) Act 2011.

Overview of the Legislative Instrument

1. This Legislative Instrument is determined pursuant to subsection 196B(8) of the Veterans' Entitlements Act 1986 (the VEA) for the purposes of the VEA and the Military Rehabilitation and Compensation Act 2004 (the MRCA).

2. This Legislative Instrument:-

  • facilitates claimants in making, and the Repatriation Commission in assessing, claims under the VEA and the MRCA respectively, by specifying the circumstances in which medical treatment and compensation can be extended to eligible persons who have malignant neoplasm of the testis and paratesticular tissues;
  • facilitates the review of such decisions by the Veterans' Review Board and the Administrative Appeals Tribunal;
  • outlines the factors which the current sound medical-scientific evidence indicates must as a minimum exist, before it can be said that a reasonable hypothesis has been raised, connecting malignant neoplasm of the testis and paratesticular tissues with the circumstances of eligible service rendered by a person, as set out in clause 4 of the Explanatory Notes;
  • replaces Instrument No. 15 of 2004; and
  • reflects developments in the available sound medical-scientific evidence concerning malignant neoplasm of the testis and paratesticular tissues which have occurred since that earlier instrument was determined. 

3. The Instrument is assessed as being a technical instrument which improves the medico-scientific quality of outcomes under the VEA and the MRCA. 

Human Rights Implications

4. This Legislative Instrument does not derogate from any human rights. It promotes the human rights of veterans, current and former Defence Force members as well as other persons such as their dependents, including:

  • the right to social security (Art 9, International Covenant on Economic, Social and Cultural Rights; Art 26, Convention on the Rights of the Child and Art 28, Convention on the Rights of Persons with Disabilities) by helping to ensure that the qualifying conditions for the benefit are 'reasonable, proportionate and transparent'[1];
  • the right to an adequate standard of living (Art 11, ICSECR; Art 27, CRC and Art 28, CRPD) by facilitating the assessment and determination of social security benefits;
  • the right to the enjoyment of the highest attainable standard of physical and mental health (Art 12, ICSECR and Art 25, CRPD), by facilitating the assessment and determination of compensation and benefits in relation to the treatment and rehabilitation of veterans and Defence Force members; and
  • the rights of persons with disabilities by facilitating the determination of claims relating to treatment and rehabilitation (Art 26, CRPD).

Conclusion

This Legislative Instrument is compatible with human rights as it does not derogate from and promotes a number of human rights.

 

Repatriation Medical Authority

 

 

 

 

 

[1] In General Comment No. 19 (The right to social security), the Committee on Economic, Social and Cultural Rights said (at paragraph 24) this to be one of the elements of ensuring accessibility to social security.

Overview

The Repatriation Medical Authority Instrument No. 3 of 2015, under subsection 196B(8) of the Veterans' Entitlements Act 1986 (VEA), revokes Instrument No. 15 of 2004 concerning malignant neoplasm of the testis and paratesticular tissues. This legislative instrument was enacted to address the need for a revised Statement of Principles to reflect the latest medical-scientific evidence regarding the relationship between such conditions and particular kinds of military service. The Authority determined this new Statement of Principles to facilitate claims under the VEA and the Military Rehabilitation and Compensation Act 2004 (MRCA), ensuring that compensation and medical treatment can be extended to eligible persons. The instrument was developed following an investigation announced in the Government Notices Gazette of 18 May 2011 and includes updated definitions, a revised format, and the addition of human immunodeficiency virus as a factor. The Instrument is compatible with human rights, promoting the rights of veterans, current and former Defence Force members, and their dependents by ensuring that qualifying conditions for benefits are reasonable, proportionate, and transparent.

Scope and Application

The Repatriation Medical Authority Instrument No. 3 of 2015, issued under the Veterans' Entitlements Act 1986 and the Military Rehabilitation and Compensation Act 2004, addresses claims concerning malignant neoplasm of the testis and paratesticular tissues, providing a revised Statement of Principles to replace the revoked Instrument No. 15 of 2004. This instrument applies to individuals who have served in various capacities, including operational, peacekeeping, hazardous, British nuclear test defence, warlike, and non-warlike services, and aims to facilitate the assessment and determination of claims for medical treatment and compensation related to these conditions. It is applicable nationally and assists in the review process by the Veterans' Review Board and the Administrative Appeals Tribunal. The instrument reflects advancements in medical-scientific evidence and specifies the minimum factors necessary to establish a connection between the service and the condition. It also ensures compatibility with human rights, promoting the rights to social security, adequate living standards, and health, particularly for veterans and their dependents.

Key Provisions

The main operative sections of the Repatriation Medical Authority Instrument No. 3 of 2015 are those that determine a new Statement of Principles concerning malignant neoplasm of the testis and paratesticular tissues. This replaces the revoked Instrument No. 15 of 2004 (section 2). The new Statement of Principles specifies the factors that must exist, which must be related to certain kinds of service, for a reasonable hypothesis to connect malignant neoplasm of the testis and paratesticular tissues with the circumstances of the service (section 4). These factors are outlined in detail within the Instrument. The Act imposes obligations on claimants, the Repatriation Commission, the Veterans' Review Board, and the Administrative Appeals Tribunal to adhere to the Statement of Principles when making, assessing, reviewing, and appealing claims related to malignant neoplasm of the testis and paratesticular tissues under the Veterans' Entitlements Act 1986 (VEA) and the Military Rehabilitation and Compensation Act 2004 (MRCA). The Statement of Principles facilitates the process by setting clear criteria that must be met for a claim to be considered valid. The Repatriation Medical Authority is responsible for determining these Statements of Principles based on sound medical-scientific evidence. Breach of the provisions in this Instrument, particularly in relation to the fraudulent misrepresentation of service-related factors, can lead to serious consequences. Under the VEA and MRCA, such breaches may result in the refusal of compensation claims, penalties for false claims, and potential criminal charges. The maximum penalties for fraud under these Acts can include fines and imprisonment, depending on the severity and intent of the breach. Additionally, any individual found to have deliberately provided false information to influence a claim may face civil litigation for damages resulting from the fraudulent claim. The Instrument ensures that the process of determining compensation claims related to malignant neoplasm of the testis and paratesticular tissues is transparent, fair, and based on the latest medical-scientific evidence. It promotes human rights by facilitating access to social security benefits and medical treatment for eligible veterans and Defence Force members. The compatibility statement affirms that the Instrument does not derogate from any human rights and, in fact, promotes several rights, including the right to social security, an adequate standard of living, and the highest attainable standard of physical and mental health.

Legal classification tags

Area of Law
Veterans' Law
Instrument
Regulation
Concepts
Definitions & Interpretation
Licensing & Registration
Compliance Obligations

Interactions

Authorises

All Versions

Sourced from the Federal Register of Legislation at 26 August 2026. For the latest information on Australian Government law please go to https://www.legislation.gov.au.